Posted on March 23rd, 2010 by
Almost all — some 94 percent — of the researchers who published favorable medical journal studies and commentaries on the controversial diabetes drug rosiglitazone had financial ties with pharmaceutical companies that manufacture it or similar drugs, a Mayo Clinic study has found…
“One-fourth of the folks who were having an opinion on this debate were not disclosing that they had a financial relationship,” said Victor Montori, MD, a Mayo Clinic endocrinologist and one of the authors of the study, in a telephone interview last week.
MinnPost, by Susan Perry, 3/22/2010
You must be logged-in to the site to post a comment.